Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1

被引：18

作者：

Fiorcari, Stefania ^{[1
]}

Maffei, Rossana ^{[2
]}

Atene, Claudio Giacinto ^{[1
]}

Mesini, Nicolo ^{[1
]}

Maccaferri, Monica ^{[2
]}

Leonardi, Giovanna ^{[2
]}

Martinelli, Silvia ^{[1
]}

Paolini, Ambra ^{[2
]}

Nasillo, Vincenzo ^{[3
]}

Debbia, Giulia ^{[1
]}

Potenza, Leonardo ^{[1
,2
]}

Luppi, Mario ^{[1
,2
]}

Marasca, Roberto ^{[1
,2
]}

机构：

[1] Univ Modena & Reggio Emilia, Sect Hematol, Dept Med & Surg Sci, Modena, Italy

[2] Azienda Osped Univ AOU Modena, Dept Hematol & Oncol, Hematol Unit, Policlin, Modena, Italy

[3] Azienda Osped Univ Modena AOU Policlin, Azienda Unita Sanit Locale Modena AUSL, Dept Lab Med & Pathol, Diagnost Hematol & Clin Genom Lab, Modena, Italy

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 11卷

关键词：

chronic lymphocytic leukemia (CLL); drug resistance; translational research; Notch; venetoclax (ABT-199); CLL; IRF4; TRANSFORMATION; INHIBITORS; EXPRESSION; MUTATIONS; SURVIVAL; CD49D; BCL2; CD23;

D O I：

10.3389/fonc.2021.777587

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution-thanks to the discovery of crucial pathogenic mechanisms. CLL is still an incurable disease due to intrinsic or acquired resistance of the leukemic clone. Venetoclax is a Bcl-2 inhibitor with a marked activity in CLL, but emerging patterns of resistance are being described. We hypothesize that intrinsic features of CLL cells may contribute to drive mechanisms of resistance to venetoclax. We analyzed the expression of Interferon Regulatory Factor 4 (IRF4), Notch2, and Mcl-1 in a cohort of CLL patients. We evaluated CLL cell viability after genetic and pharmaceutical modulation of Notch2 expression in patients harboring trisomy 12. We tested venetoclax in trisomy 12 CLL cells either silenced or not for Notch2 expression or in combination with an inhibitor of Mcl-1, AMG-176. Trisomy 12 CLL cells were characterized by low expression of IRF4 associated with high levels of Notch2 and Mcl-1. Notch2 and Mcl-1 expression determined protection of CLL cells from spontaneous and drug-induced apoptosis. Considering the involvement of Mcl-1 in venetoclax resistance, our data demonstrated a contribution of high levels of Notch2 and Mcl-1 in a reduced response to venetoclax in CLL cells carrying trisomy 12. Furthermore, reduction of Mcl-1 expression by silencing Notch2 or by treatment with AMG-176 was able to restore the response of CLL cells to venetoclax. The expression of Notch2 identifies a subset of CLL patients, mainly harboring trisomy 12, characterized by high levels of Mcl-1. This biological mechanism may compromise an effective response to venetoclax.

引用

页数：10

共 38 条

[1] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax [J].

Anderson, Mary Ann ;

Tam, Constantine ;

Lew, Thomas E. ;

Juneja, Surender ;

Juneja, Manu ;

Westerman, David ;

Wall, Meaghan ;

Lade, Stephen ;

Gorelik, Alexandra ;

Huang, David C. S. ;

Seymour, John F. ;

Roberts, Andrew W. .

BLOOD, 2017, 129 (25) :3362-3370

[2] Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications (vol 34, pg 462, 2020) [J].

Arruga, Francesca ;

Bracciama, Valeria ;

Vitale, Nicoletta ;

Vaisitti, Tiziana ;

Gizzi, Katiuscia ;

Yeomans, Alison ;

Coscia, Marta ;

D'Arena, Giovanni ;

Gaidano, Gianluca ;

Allan, John N. ;

Furman, Richard R. ;

Packham, Graham ;

Forconi, Francesco ;

Deaglio, Silvia .

LEUKEMIA, 2020, 34 (06) :1721-1721

[3] B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion [J].

Asslaber, Daniela ;

Qi, Yuan ;

Maeding, Nicole ;

Steiner, Markus ;

Denk, Ursula ;

Hoepner, Jan Philip ;

Hartmann, Tanja Nicole ;

Zaborsky, Nadja ;

Greil, Richard ;

Egle, Alexander .

BLOOD, 2019, 134 (20) :1717-1729

[4] NOTCH1 mutations in CLL associated with trisomy 12 [J].

Balatti, Veronica ;

Bottoni, Arianna ;

Palamarchuk, Alexey ;

Alder, Hansjuerg ;

Rassenti, Laura Z. ;

Kipps, Thomas J. ;

Pekarsky, Yuri ;

Croce, Carlo M. .

BLOOD, 2012, 119 (02) :329-331

[5] Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease [J].

Blombery, Piers .

LEUKEMIA & LYMPHOMA, 2020, 61 (02) :257-262

[6] Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma [J].

Blombery, Piers ;

Birkinshaw, Richard W. ;

Nguyen, Tamia ;

Gong, Jia-nan ;

Thompson, Ella R. ;

Xu, Zhen ;

Westerman, David A. ;

Czabotar, Peter E. ;

Dickinson, Michael ;

Huang, David C. S. ;

Seymour, John F. ;

Roberts, Andrew W. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) :E188-E191

[7] BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199 [J].

Bojarczuk, Kamil ;

Sasi, Binu K. ;

Gobessi, Stefania ;

Innocenti, Idanna ;

Pozzato, Gabriele ;

Laurenti, Luca ;

Efremov, Dimitar G. .

BLOOD, 2016, 127 (25) :3192-3201

[8] AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies [J].

Caenepeel, Sean ;

Brown, Sean P. ;

Belmontes, Brian ;

Moody, Gordon ;

Keegan, Kathleen S. ;

Chui, Danny ;

Whittington, Douglas A. ;

Huang, Xin ;

Poppe, Leszek ;

Cheng, Alan C. ;

Cardozom, Mario ;

Houze, Jonathan ;

Li, Yunxiao ;

Lucas, Brian ;

Paras, Nick A. ;

Wang, Xianghong ;

Taygerly, Joshua P. ;

Vimolratana, Marc ;

Zancanella, Manuel ;

Zhu, Liusheng ;

Cajulis, Elaina ;

Osgood, Tao ;

Sun, Jan ;

Damon, Leah ;

Egan, Regina K. ;

Greninger, Patricia ;

McClanaghan, Joseph D. ;

Gong, Jianan ;

Moujalled, Donia ;

Pomilio, Giovanna ;

Beltran, Pedro ;

Benes, Cyril H. ;

Roberts, Andrew W. ;

Huang, David C. ;

Wei, Andrew ;

Canon, Jude ;

Coxon, Angela ;

Hughes, Paul E. .

CANCER DISCOVERY, 2018, 8 (12) :1582-1597

[9] Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome [J].

Chigrinova, Ekaterina ;

Rinaldi, Andrea ;

Kwee, Ivo ;

Rossi, Davide ;

Rancoita, Paola M. V. ;

Strefford, Jonathan C. ;

Oscier, David ;

Stamatopoulos, Kostas ;

Papadaki, Theodora ;

Berger, Francoise ;

Young, Ken H. ;

Murray, Fiona ;

Rosenquist, Richard ;

Greiner, Timothy C. ;

Chan, Wing C. ;

Orlandi, Ester M. ;

Lucioni, Marco ;

Marasca, Roberto ;

Inghirami, Giorgio ;

Ladetto, Marco ;

Forconi, Francesco ;

Cogliatti, Sergio ;

Votavova, Hana ;

Swerdlow, Steven H. ;

Stilgenbauer, Stephan ;

Piris, Miguel A. ;

Matolcsy, Andras ;

Spagnolo, Dominic ;

Nikitin, Eugene ;

Zamo, Alberto ;

Gattei, Valter ;

Bhagat, Govind ;

Ott, German ;

Zucca, Emanuele ;

Gaidano, Gianluca ;

Bertoni, Francesco .

BLOOD, 2013, 122 (15) :2673-2682

[10] MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies [J].

Choudhary, G. S. ;

Al-Harbi, S. ;

Mazumder, S. ;

Hill, B. T. ;

Smith, M. R. ;

Bodo, J. ;

Hsi, E. D. ;

Almasan, A. .

CELL DEATH & DISEASE, 2015, 6 :e1593-e1593

← 1 2 3 4 →